Donnie Bunch
Family Medicine · London, KYNPI 1609034420
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 430 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 17.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,754 and has fallen 71.4% since, to $501 in 2025. Among family medicine clinicians in KY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 430 payments — averaging $15.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AbbVie$1K
- Lilly USA, LLC$566
- Novartis$518
- Pfizer$442
- Amgen$353
- plus $3K from 31 others
What the payments were for
- Food & beverage$6,634100%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 83 | $1,138 |
| AbbVie(2 entities) | 58 | $1,065 |
| Lilly USA, LLC | 45 | $566 |
| Novartis | 29 | $518 |
| Pfizer | 37 | $442 |
| Amgen | 24 | $353 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 17 | $286 |
| GSK | 11 | $260 |
| Merck | 21 | $260 |
| Abbott | 10 | $189 |
| Amarin Pharma, Inc. | 14 | $187 |
| AstraZeneca | 7 | $164 |
| Johnson & Johnson | 9 | $146 |
| Bayer | 6 | $93 |
| Astellas Pharma US Inc | 6 | $84 |
| Axsome Therapeutics, Inc. | 3 | $78 |
| Boehringer Ingelheim | 5 | $70 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $67 |
| Pacira Therapeutics, Inc. | 4 | $65 |
| Corcept Therapeutics | 3 | $57 |
| Clarus Therapeutics Inc. | 3 | $57 |
| Sanofi | 3 | $55 |
| Sanofi-aventis U.S. LLC | 3 | $52 |
| Genentech USA, Inc. | 3 | $48 |
| Sumitomo Pharma America, Inc. | 2 | $46 |
| Esperion Therapeutics, Inc. | 2 | $40 |
| Teva Pharmaceuticals USA, Inc. | 3 | $39 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $38 |
| Radius Health, Inc. | 2 | $28 |
| Phathom Pharmaceuticals, Inc. | 2 | $27 |
| Supernus Pharmaceuticals, Inc. | 2 | $24 |
| Halozyme Inc | 1 | $22 |
| Insulet Corporation | 2 | $22 |
| Lundbeck LLC | 1 | $15 |
| Biohaven Pharmaceuticals, Inc. | 1 | $15 |
| Evoke Pharma, Inc. | 1 | $14 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,643 in reported general payments places this provider in the 90th percentile of 1,559 family medicine providers in Kentucky.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RinvoqUpadacitinib | 14 | $92,352 |
| EliquisApixaban | 78 | $89,704 |
| OzempicSemaglutide | 58 | $66,245 |
| FarxigaDapagliflozin Propanediol | 27 | $38,934 |
| JanuviaSitagliptin Phosphate | 26 | $38,652 |
| MounjaroTirzepatide | 32 | $38,607 |
| EntrestoSacubitril/Valsartan | 28 | $35,711 |
| JardianceEmpagliflozin | 32 | $35,099 |
| Tresiba Flextouch U-100Insulin Degludec | 20 | $22,393 |
| Tresiba Flextouch U-200Insulin Degludec | 22 | $17,589 |
| VraylarCariprazine Hcl | 11 | $14,780 |
| TrulicityDulaglutide | 14 | $14,477 |
| LinzessLinaclotide | 20 | $13,306 |
| BrilintaTicagrelor | 15 | $10,764 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $9,761 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq, Vraylar, Linzess | $1,065 | $120,43845 claims |
| PfizerEliquis | $442 | $89,70478 claims |
| Novo NordiskOzempic | $1,138 | $66,24558 claims |
| Lilly USA, LLCMounjaro, Trulicity | $566 | $53,08446 claims |
| AstraZenecaFarxiga, Brilinta, Symbicort | $164 | $52,73054 claims |
| MerckJanuvia | $260 | $38,65226 claims |
| NovartisEntresto | $518 | $35,71128 claims |
| Boehringer IngelheimJardiance | $70 | $35,09932 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,559 family medicine providers in Kentucky.
Other family medicine in London
- Jackie MaxeyLondon$12K
- Christopher RhyneLouisville$933K
- John RichardLexington$226K
- James TurnboPaducah$124K
- Edward SchumannFlorence$79K
- Ronald KoffNew Castle$71K
- Suraj GathaniLouisville$69K
- Bradley GrayFlorence$51K
- Jackie KazeeAshland$45K
- Mandy WhittLouisville$38K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.